Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC)
-
- João P. M. Nunes
- Department of Chemistry
-
- Vessela Vassileva
- UCL Cancer Institute
-
- Eifion Robinson
- Department of Chemistry
-
- Maurício Morais
- Department of Chemistry
-
- Mark E. B. Smith
- Department of Chemistry
-
- R. Barbara Pedley
- UCL Cancer Institute
-
- Stephen Caddick
- Department of Chemistry
-
- James R. Baker
- Department of Chemistry
-
- Vijay Chudasama
- Department of Chemistry
説明
<p>Conjugation of next generation maleimides to engineered cysteines in a THIOMAB™ antibody delivers a highly stable and potent THIOMAB™ antibody-drug conjugate.</p>
収録刊行物
-
- RSC Advances
-
RSC Advances 7 (40), 24828-24832, 2017
Royal Society of Chemistry (RSC)